Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First in Human, Multiple-dose, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-050/NCNP-03 in Boys With Duchenne Muscular Dystrophy (DMD)

NCT06053814 is registered in ClinicalTrials.gov with NS Pharma, Inc. as lead sponsor.

NCT NCT06053814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06053814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First in Human, Multiple-dose, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-050/NCNP-03 in Boys With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
NS Pharma, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 18, 2024
Completion date
March 31, 2028
Enrollment
20 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy